Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

A. Ribas; J. D. Wolchok; C. Robert; R. Kefford; O. Hamid; A. Daud; W-J. Hwu; J. S. Weber; A. M. Joshua; T. C. Gangadhar; A. Patnaik; P. Hersey; R. Dronca; H. Zarour; K. Gergich; J. A. Lindia; M. Giannotti; X. N. Li; S. Ebbinghaus; S. P. Kang; F. S. Hodi

doi:10.1016/j.ejca.2015.06.072

Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

A. Ribas, J. D. Wolchok, C. Robert, R. Kefford, O. Hamid, A. Daud, W-J. Hwu, J. S. Weber, A. M. Joshua, T. C. Gangadhar, A. Patnaik, P. Hersey, R. Dronca, H. Zarour, K. Gergich, J. A. Lindia, M. Giannotti, X. N. Li, S. Ebbinghaus, S. P. KangF. S. Hodi

Research output: Contribution to journal › Meeting abstract

Original language	English
Article number	P0116
Pages (from-to)	E24
Number of pages	1
Journal	European Journal of Cancer
Volume	51
Issue number	Supplement 2
DOIs	https://doi.org/10.1016/j.ejca.2015.06.072
Publication status	Published - Jul 2015
Externally published	Yes
Event	7th Annual Asian Oncology Summit / 11th Annual Conference of the Organisation-for-Oncology-and-Translational-Research - Shanghai Duration: 10 Apr 2015 → 12 Apr 2015

Access to Document

10.1016/j.ejca.2015.06.072

Cite this

Ribas, A., Wolchok, J. D., Robert, C., Kefford, R., Hamid, O., Daud, A., Hwu, W.-J., Weber, J. S., Joshua, A. M., Gangadhar, T. C., Patnaik, A., Hersey, P., Dronca, R., Zarour, H., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., ... Hodi, F. S. (2015). Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma. European Journal of Cancer, 51(Supplement 2), E24. Article P0116. https://doi.org/10.1016/j.ejca.2015.06.072

@article{33bf9c50ba1f4c2aad5fc4a8ad50390e,

title = "Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma",

author = "A. Ribas and Wolchok, {J. D.} and C. Robert and R. Kefford and O. Hamid and A. Daud and W-J. Hwu and Weber, {J. S.} and Joshua, {A. M.} and Gangadhar, {T. C.} and A. Patnaik and P. Hersey and R. Dronca and H. Zarour and K. Gergich and Lindia, {J. A.} and M. Giannotti and Li, {X. N.} and S. Ebbinghaus and Kang, {S. P.} and Hodi, {F. S.}",

year = "2015",

month = jul,

doi = "10.1016/j.ejca.2015.06.072",

language = "English",

volume = "51",

pages = "E24",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

number = "Supplement 2",

note = "7th Annual Asian Oncology Summit / 11th Annual Conference of the Organisation-for-Oncology-and-Translational-Research ; Conference date: 10-04-2015 Through 12-04-2015",

}

Ribas, A, Wolchok, JD, Robert, C, Kefford, R, Hamid, O, Daud, A, Hwu, W-J, Weber, JS, Joshua, AM, Gangadhar, TC, Patnaik, A, Hersey, P, Dronca, R, Zarour, H, Gergich, K, Lindia, JA, Giannotti, M, Li, XN, Ebbinghaus, S, Kang, SP & Hodi, FS 2015, 'Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma', European Journal of Cancer, vol. 51, no. Supplement 2, P0116, pp. E24. https://doi.org/10.1016/j.ejca.2015.06.072

TY - JOUR

T1 - Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

AU - Ribas, A.

AU - Wolchok, J. D.

AU - Robert, C.

AU - Kefford, R.

AU - Hamid, O.

AU - Daud, A.

AU - Hwu, W-J.

AU - Weber, J. S.

AU - Joshua, A. M.

AU - Gangadhar, T. C.

AU - Patnaik, A.

AU - Hersey, P.

AU - Dronca, R.

AU - Zarour, H.

AU - Gergich, K.

AU - Lindia, J. A.

AU - Giannotti, M.

AU - Li, X. N.

AU - Ebbinghaus, S.

AU - Kang, S. P.

AU - Hodi, F. S.

PY - 2015/7

Y1 - 2015/7

U2 - 10.1016/j.ejca.2015.06.072

DO - 10.1016/j.ejca.2015.06.072

M3 - Meeting abstract

SN - 0959-8049

VL - 51

SP - E24

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - Supplement 2

M1 - P0116

T2 - 7th Annual Asian Oncology Summit / 11th Annual Conference of the Organisation-for-Oncology-and-Translational-Research

Y2 - 10 April 2015 through 12 April 2015

ER -